Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and…
A planned interim clinical trial analysis found Praxis Precision Medicines drug ulixacaltamide was unlikely to succeed as a treatment for essential tremor. But Praxis is continuing two late-stage tests of the drug; data are expected in the third quarter of 2025. The post Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers…
Customers are no longer willing to accept vague assurances about security. Instead, they expect evidence of secure design, documented vulnerability management processes, and transparency about software components. The post Healthcare’s Security Awakening Testing Patience of Medical Device Buyers appeared first on MedCity News.
As public trust in the U.S. healthcare system declines, Intermountain Health CEO Rob Allen thinks that nonprofit hospitals can do a better job showcasing how they reinvest in their communities. He pointed to Intermountain’s work in areas like affordable housing, food access and charity care as examples of nonprofit providers’ often-overlooked value. The post Intermountain…
Under estate recovery, state Medicaid programs are required to recover the costs of long-term care and related hospital and prescription drug services for enrollees ages 55 and older. KFF examines the wide variation in estate recovery practices across states as well as the criticisms of this policy, which have led to federal proposals to modify…
This brief reviews current federal and state policies on Medicaid and insurance coverage of abortion services in the U.S. and presents national and state estimates on the availability of abortion coverage for people enrolled in private plans, Marketplace plans, and Medicaid.
This fact sheet shares information about the World Health Organization (WHO) and U.S. government funding and engagement with WHO.
AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared at a medical conference next month, but it appears the RNA therapy’s slim hopes now ride on a subgroup analysis. The post Phase 3 Failure Keeps AstraZeneca and Ionis Out…
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…
By JEFF GOLDSMITH In late June, 2024, two economists, Zarek Brot-Goldberg and Zack Cooper, from the University of Chicago and Yale respectively, released an economic analysis arguing that hospital mergers damage local economies and result in an increase in deaths by suicide and drug overdoses in the markets where mergers occur. Funded by Arnold Ventures…